Breaking Finance News

Charles River Laboratories Intl. Inc (NYSE:CRL) has been upgraded to Strong-Buy in a statement by BidaskClub earlier today.

BidaskClub has upgraded Charles River Laboratories Intl. Inc (NYSE:CRL) to Strong-Buy in a statement released on 6/20/2017.

On Friday May 12, 2017, Citigroup released a statement on Charles River Laboratories Intl. Inc (NYSE:CRL) upped the target price from $0.00 to $104.00 that suggested an upside of 0.18%.

Having a price of $99.10, Charles River Laboratories Intl. Inc (NYSE:CRL) traded -0.27% lower on the day. With the last close up 11.27% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.04% over the same period. CRL has recorded a 50-day average of $103.01 and a two hundred day average of $95.28. Trade Volume was up over the average, with 572,862 shares of CRL changing hands over the typical 351,855

Recent Performance Chart

Charles River Laboratories Intl. Inc (NYSE:CRL)

Charles River Laboratories Intl. Inc has PE ratio of 27.94 with a one year low of $67.20 and a one year high of $109.59 and has a market capitalization of $0.

A total of 15 analysts have released a report on Charles River Laboratories Intl. Inc. Six analysts rating the company a strong buy, three analysts rating the company a buy, eight analysts rating the company a hold, two analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $85.47.

General Company Details For Charles River Laboratories Intl. Inc (NYSE:CRL)

Charles River Laboratories International, Inc. is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development. The Company operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment includes Research Models and Research Model Services. The DSA segment includes Discovery Services and Safety Assessment. The Manufacturing segment includes Microbial Solutions, Avian, Biologics and Contract Manufacturing. The Company also provides a suite of products and services to support the Company's clients' manufacturing activities.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.